DEVONIAN HEALTH GROUP INC.
For immediate release
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Devonian Announces Grant of Options.
QUEBEC, Québec – July 07, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“)
(TSXV: GSD) announces that the Board of Directors has approved the grant of options (the ‘‘Options’’) to
purchase common shares in the capital of the Corporation. Such options are exercisable at a price of
$0.60 and for a period of five years from the date of grant. An aggregate of 860,000 options was granted
to certain directors and consultants of the Corporation. Such options vest on the grant date.
Additionally, the Company has granted 300,000 stock options to managements and employees of the
Corporation. Twenty-five (25%) of these granted options vest on the grant date and then 25% yearly over
the following years.
Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and
anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as
well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now
moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis.
While the development of prescription botanical drugs is its core business, Devonian is also involved in
the development of high value derma-cosmeceutical products as part of a secondary strategy to generate
short-term revenues and optimize manufacturing efficiency.
For more information about Devonian Health Group Inc., visit www.groupedevonian.com.
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
President and Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509